DiaMedica Therapeutics Announces Closing of Private Placement
20 mars 2018 17h40 HE
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, March 20, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the “Company”) (TSX-V:DMA) (OTCQB:DMCAF) is pleased to announce the successful completion of the first closing of a...
DiaMedica Announces First Enrollment in its PHASE 2 “REMEDY” TRIAL for Acute Ischemic Stroke
22 févr. 2018 07h00 HE
|
DiaMedica Therapeutics Inc.
DM199 may offer an effective and safe treatment with a significantly longer treatment window (24 hours) compared to the current standard of careREMEDY trial lead by prominent neurologist Dr. Bruce...
DiaMedica to Present at the 14th Annual Noble Investor Conference
29 janv. 2018 08h45 HE
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, Jan. 29, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (TSXV:DMA) (OTCQB:DMCAF), today announced that Mr. Rick Pauls, its President and CEO, will present at Noble Capital...
DiaMedica Letter to Shareholders
18 janv. 2018 08h00 HE
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, Jan. 18, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (“DiaMedica”) (TSX VENTURE:DMA) (OTCQB:DMCAF), provides corporate update. As we enter into 2018, we wanted to thank you,...
DiaMedica Therapeutics Announces Results of Annual General and Special Meeting of Shareholders
21 déc. 2017 18h48 HE
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, Dec. 21, 2017 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (TSX-V:DMA) (OTCQB:DMCAF) (the “Company”), today announced that at its Annual General and Special Meeting (the “Meeting”)...
DiaMedica Therapeutics Completes Non-Brokered Private Placement
18 déc. 2017 19h41 HE
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, Dec. 18, 2017 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the “Company”) (TSX-V:DMA) (OTCQB:DMCAF) announced today the closing of its previously announced non-brokered private...
DiaMedica Therapeutics Announces Non-Brokered Private Placement
13 déc. 2017 16h48 HE
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, Dec. 13, 2017 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the “Company”) (TSX-V:DMA) (OTCQB:DMCAF), announces that, subject to TSX Venture Exchange approval, it is undertaking a...
DiaMedica Therapeutics Announces Ethics Committee Clearance at First Site to Initiate REMEDY Phase 2 Trial for Acute Ischemic Stroke
22 nov. 2017 08h00 HE
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, Nov. 22, 2017 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the “Company”) (TSX Venture:DMA) (OTCQB:DMCAF), announced it has received ethics committee approval to initiate the first...
DiaMedica Accelerates Warrant Expiry Date
20 nov. 2017 15h12 HE
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, Nov. 20, 2017 (GLOBE NEWSWIRE) -- DiaMedica (TSX-V:DMA) today on behalf of the board of directors announces that in accordance with the terms of the warrant indenture for warrants...
DiaMedica Therapeutics Announces Publication of Positive Clinical Results for DM199 in the International Journal of Clinical Trials
07 nov. 2017 08h00 HE
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, Nov. 07, 2017 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the “Company”) (TSX Venture:DMA) (OTCQB:DMCAF), a clinical stage biopharmaceutical company focused on improving the lives...